|Articles|November 1, 2001

Understanding the Hormone Continuum: From Menarche to Menopause
Volume 7
Issue 18 Suppl

Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Download PDF: Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Articles in this issue

over 24 years ago

Article

Introduction

over 24 years ago

Article

The Managed Care Pharmacy Perspective

over 24 years ago

Article

Managing the Transition from Oral Contraceptives to Hormone Replacement Therapy

over 24 years ago

Article

Patient Communication and Counseling on Contraception and Hormone Replacement Therapy

over 24 years ago

Article

CPE Quiz

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Pharmacologic Characteristics of Progestins Used for Contraception and Hormone Replacement Therapy, Including New Transdermal Technologies

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS